Golden
Cell Medica

Cell Medica

Cell Medica is a biotechnology developing immunotherapies for the treatment of human diseases.

All edits

Edits on 28 Jul 2019
Henry Ogolla
Henry Ogolla approved a suggestion from Golden's AI on 28 Jul 2019 4:45 pm
Edits made to:
Infobox (+2 properties)
Edits on 19 Mar 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 19 Mar 2019 10:46 pm
Edits made to:
Article (+14/-14 characters)

Article

On July 23, 2012 Cell Medica completed their series A funding round with $26.5 in funding from Wellcome TrustWellcome Trust, Imperial Innovations, and Invesco Perpetual. 

Edits on 16 Mar 2019
Dawson Sewell
Dawson Sewell edited on 16 Mar 2019 1:25 pm
Edits made to:
Infobox (+9 properties)
Timeline (+3 events) (+588 characters)
Description (+95 characters)
Article (+728 characters)
People (+1 rows) (+2 cells) (+20 characters)
Further reading (+4 rows) (+16 cells) (+717 characters)
Categories (+2 topics)
Related Topics (+2 topics)
Topic thumbnail

Cell Medica

Cell Medica is a biotechnology developing immunotherapies for the treatment of human diseases.

Article



Cell Medica is a biotechnology developing immunotherapies for the treatment of human diseases that is headquartered in London, England and was founded in 2005 by Gregg Sando.

Funding

Series A

On July 23, 2012 Cell Medica completed their series A funding round with $26.5 in funding from Wellcome Trust, Imperial Innovations, and Invesco Perpetual. 

Series B

On November 25, 2014 Cell Medica completed their series B funding round with $78 million in funding from Woodford Investment Management, Imperial Innovations, and Invesco Perpetual. 

Series C

On March 15, 2017 Cell Medica completed their series C funding round with $74 million in funding from Touchstone Innovations, Woodford Investment Management, and Invesco Perpetual. 

People

Name
Role
Related Golden topics

Gregg Sando

Founder



Further reading

Title
Author
Link
Type

CAR-T player Cell Medica names Kite's European chief as CEO

Nick Paul Taylor

Web

Privately-owned UK biotech Cell Medica has named Chris Nowers its new chief executive after its founder...

The Pharma Letter

Web

T-cell immunotherapy firm Cell Medica rakes in $78M in Imperial-led series B

Nuala Moran

Web

The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue

Evelyn Warner

Web

Infobox

Categories

Related Topics

Timeline

March 15, 2017

Series C funding round

On March 15, 2017 Cell Medica completed their series C funding round with $74 million in funding from Touchstone Innovations, Woodford Investment Management, and Invesco Perpetual. 

November 25, 2014

Series B funding round

On November 25, 2014 Cell Medica completed their series B funding round with $78 million in funding from Woodford Investment Management, Imperial Innovations, and Invesco Perpetual. 

July 23, 2012

Series A funding round

On July 23, 2012 Cell Medica completed their series A funding round with $26.5 in funding from Wellcome Trust, Imperial Innovations, and Invesco Perpetual. 

Dawson Sewell"Initial topic creation"
Dawson Sewell created this topic on 16 Mar 2019 12:56 pm
Edits made to:
Topic thumbnail

 Cell Medica

Cell Medica is a biotechnology developing immunotherapies for the treatment of human diseases.

No more activity to show.